Pharmacological agents are being developed to modulate phosphotyrosyl (pTyr) dependent cell signalling. Emphasis is on inhibitors of pTyr dependent binding interactions, which are mediated by src homology 2 (SH2) domains and on protein- tyrosine phosphatase (PTP) inhibitors. In the SH2 domain area, development of cell-permeable growth factor receptor-bound protein 2 (Grb2) antagonists is being undertaken as potential new therapeutics for a variety of cancers including erbB-2 and Met dependent cancers. Previously we had prepared a series of pTyr mimicking amino acid analogues that were stable toward enzymatic degradation. These were incorporated into tripeptide platforms and shown to have high Grb2-SH2 domain-binding affinity. During the reporting period novel macrocycles were prepared that represented conformationally constrained tetrapeptide-mimicking variants of our earlier tripeptide inhibitors. In extracellular Grb2-SH2 domain binding assays, these new macrocyclic compounds displayed significantly enhanced potency. For certain analogues, binding constants in the low picomolar range were observed. Importantly, in whole cell assays these macrocyclic ligands maintained superior potency, with in vivo inhibition constants against Grb2 SH2 domain binding being in the low nanomolar range. In culture against breast cancer cells that are mitogenically-driven through erB-2 dependent pathways that utilize Grb2, these macrocycles displayed cytostatic effects at submicromolar concentrations. The same compounds were non-toxic against similar cells that are not dependent on Grb2 pathways for survival. In a parallel collaboration effects were studied against von Hippel-Lindau (VHL)-dependent kidney cancers that rely on Grb2-dependent signaling pathways. In cellular studies, these agents inhibit hepatocyte growth factor (HGF)-induced cell migration in Met containing fibroblasts at nanomolar concentrations and inhibit tubule formation potentially involved in angiogenesis. Work continues on the design, synthesis and biological evaluation of new macrocyclic Grb2 SH2 domain-signaling inhibitors. Recent progress includes the design and synthesis of a new class of macrocyclic Grb2 SH2 domain-binding inhibitor that is derived from the ring-closing metathesis (RCM) of C terminal allylglycine amides with N-terminal beta-vinyl pTyr mimetics. In further work, a series of phosphoryl-mimicking groups were incorporated into pTyr mimetics and expressed in a high affinity Grb2 SH2 domain-binding macrocyclic platform. In collaborative studies, the X-ray crystal structure was solved of one of these inhibitors bound to the Grb2 SH2 domain. In the phosphatase area, a structure-based approach toward PTP inhibitor design is being pursued. Using as a display platform, a tripeptide sequence derived from an epidermal growth factor receptor (EGFr) autophosphorylation site, we examined a panel of synthetic pTyr mimetics for inhibitory potencies against YopH, which is a pathogenic PTP component of Yersinia pestis, the causative agent of plague. Certain of these tripeptides exhibited binding constants in the single-digit micromolar range. Work is ongoing to optimize these tripeptide leads as potential therapeutics for the treatment of plague. Such therapeutics may have value against the use of Yersinia pestis as a bioterrorism agent.

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC006198-15
Application #
7048176
Study Section
(LMC)
Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
2004
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Liu, Fa; Park, Jung-Eun; Qian, Wen-Jian et al. (2011) Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Nat Chem Biol 7:595-601
Liu, Fa; Park, Jung-Eun; Lee, Kyung S et al. (2009) Preparation of orthogonally protected (2S, 3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) as a phosphatase-stable phosphothreonine mimetic and its use in the synthesis of Polo-box domain-binding peptides. Tetrahedron 65:9673-9679
Jiang, Sheng; Liao, Chenzhong; Bindu, Lakshman et al. (2009) Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity. Bioorg Med Chem Lett 19:2693-8
Cao, Xuefei; Plasencia, Carmen; Kanzaki, Atsuko et al. (2009) Elucidation of the molecular mechanisms of a salicylhydrazide class of compounds by proteomic analysis. Curr Cancer Drug Targets 9:189-201
Liu, Fa; Worthy, Karen M; Bindu, Lakshman K et al. (2007) Structural examination of ring-closing metathesis-derived 15-member macrocycles as Grb2 SH2 domain-binding tetrapeptide mimetics. J Org Chem 72:9635-42
Giubellino, Alessio; Gao, Yang; Lee, Sunmin et al. (2007) Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res 67:6012-6
Kang, Sang-Uk; Choi, Won Jun; Oishi, Shinya et al. (2007) Examination of acylated 4-aminopiperidine-4-carboxylic acid residues in the phosphotyrosyl+1 position of Grb2 SH2 domain-binding tripeptides. J Med Chem 50:1978-82
Choi, Won Jun; Shi, Zhen-Dan; Worthy, Karen M et al. (2006) Application of azide-alkyne cycloaddition 'click chemistry' for the synthesis of Grb2 SH2 domain-binding macrocycles. Bioorg Med Chem Lett 16:5265-9
Dharmawardana, Pathirage G; Peruzzi, Benedetta; Giubellino, Alessio et al. (2006) Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. Anticancer Drugs 17:13-20
Kang, Sang-Uk; Shi, Zhen-Dan; Worthy, Karen M et al. (2005) Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform. J Med Chem 48:3945-8

Showing the most recent 10 out of 37 publications